Stay updated on Pembrolizumab vs BCG in High-Risk NMIBC & NMI-UTUC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs BCG in High-Risk NMIBC & NMI-UTUC Clinical Trial page.

Latest updates to the Pembrolizumab vs BCG in High-Risk NMIBC & NMI-UTUC Clinical Trial page
- CheckyesterdayChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as the introduction of pembrolizumab, while several specific terms and resources related to cancer treatment have been removed.SummaryDifference3%
- Check8 days agoNo Change Detected
- Check16 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check23 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check30 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.9%
- Check37 days agoChange DetectedThe web page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about HHS Vulnerability Disclosure.SummaryDifference0.2%
- Check44 days agoChange DetectedThe web page has been updated from version 2.16.5 to version 2.16.6.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab vs BCG in High-Risk NMIBC & NMI-UTUC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs BCG in High-Risk NMIBC & NMI-UTUC Clinical Trial page.